Clinical Trials Directory

Trials / Completed

CompletedNCT04435223

Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen

Status
Completed
Phase
Study type
Observational
Enrollment
62 (actual)
Sponsor
Centre Hospitalier Universitaire Dijon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

SARS-COV 2 infection might be responsible for sever pneumonia. Obesity seems to be a risk factor for severe SARS-COV 2 pneumonia. Lipid metabolism alteration are described with both obesity and sepsis. The aim of the present study was to describe association between lipid metabolism, obesity, sepsis inflammation and clinical outcome in COVID-19 patient with severe pneumonia compared with severe pneumonia caused by other pathogenes.

Conditions

Interventions

TypeNameDescription
BIOLOGICALbiological assays in particular on the lipid metabolismbioassays carried out on samples already collected and conserved

Timeline

Start date
2020-04-07
Primary completion
2020-05-07
Completion
2020-05-07
First posted
2020-06-17
Last updated
2026-02-02

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04435223. Inclusion in this directory is not an endorsement.

Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen (NCT04435223) · Clinical Trials Directory